Australia markets open in 7 hours 32 minutes

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
134.54-0.03 (-0.02%)
As of 12:28PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 13.54B
Enterprise value 12.85B
Trailing P/E 36.57
Forward P/E 27.32
PEG ratio (5-yr expected) 0.46
Price/sales (ttm)6.97
Price/book (mrq)5.68
Enterprise value/revenue 6.48
Enterprise value/EBITDA 25.85

Trading information

Stock price history

Beta (5Y monthly) 0.36
52-week change 340.05%
S&P500 52-week change 326.24%
52-week high 3148.37
52-week low 393.02
50-day moving average 3137.07
200-day moving average 3127.90

Share statistics

Avg vol (3-month) 3794.77k
Avg vol (10-day) 3792.94k
Shares outstanding 5100.64M
Implied shares outstanding 6100.64M
Float 899.41M
% held by insiders 11.00%
% held by institutions 196.12%
Shares short (15 May 2024) 41.86M
Short ratio (15 May 2024) 42.4
Short % of float (15 May 2024) 42.16%
Short % of shares outstanding (15 May 2024) 41.85%
Shares short (prior month 15 Apr 2024) 42.02M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 429 Dec 1995
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024


Profit margin 18.65%
Operating margin (ttm)20.43%

Management effectiveness

Return on assets (ttm)10.08%
Return on equity (ttm)18.16%

Income statement

Revenue (ttm)1.98B
Revenue per share (ttm)20.15
Quarterly revenue growth (yoy)22.60%
Gross profit (ttm)N/A
Net income avi to common (ttm)369.7M
Diluted EPS (ttm)3.67
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.21B
Total cash per share (mrq)12.03
Total debt (mrq)410.7M
Total debt/equity (mrq)17.21%
Current ratio (mrq)2.52
Book value per share (mrq)23.72

Cash flow statement

Operating cash flow (ttm)645.4M
Levered free cash flow (ttm)719.32M